{
  "summary": {
    "total_tests": 100,
    "equivalent_results": 57,
    "different_results": 43,
    "high_significance_differences": 18,
    "medium_significance_differences": 25,
    "low_significance_differences": 0,
    "differences_by_focus": {
      "blast_thresholds": 6,
      "mds_blast_ranges": 12,
      "aml_vs_mds_borderline": 5,
      "age_dependent_differences": 5,
      "tp53_terminology": 5,
      "disease_type_disagreement": 2,
      "complex_cytogenetics": 1,
      "comutation_patterns": 1,
      "erythroid_handling": 3,
      "therapy_evolution": 2,
      "combination_scenarios": 1
    },
    "differences_by_category": {
      "major_category_difference": 9,
      "category_difference": 15,
      "mds_aml_hybrid_difference": 10,
      "diagnostic_uncertainty": 9
    }
  },
  "test_results": [
    {
      "test_id": "test_000001",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.011802"
    },
    {
      "test_id": "test_000002",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.011879"
    },
    {
      "test_id": "test_000003",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.011920"
    },
    {
      "test_id": "test_000004",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.011960"
    },
    {
      "test_id": "test_000005",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "young_adult_npm1_aml",
        "scenario_description": "Young adult with NPM1+ AML - good prognosis group",
        "blasts_percentage": 85,
        "age": 28
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 85",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 85",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:53:52.011980"
    },
    {
      "test_id": "test_000006",
      "input_data": {
        "test_name": "blast_18_with_srsf2_u2af1",
        "description": "18% blasts with SRSF2 and U2AF1 mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "MDS_related_mutation": {
          "SRSF2": true,
          "U2AF1": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:53:52.012017"
    },
    {
      "test_id": "test_000007",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.012042"
    },
    {
      "test_id": "test_000008",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.012076"
    },
    {
      "test_id": "test_000009",
      "input_data": {
        "test_name": "erythroid_blast_18_dysplastic",
        "description": "18% blasts with erythroid predominance and dysplasia",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_differentiation": "M6",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "AML_differentiation: M6",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:53:52.012110"
    },
    {
      "test_id": "test_000010",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.012142"
    },
    {
      "test_id": "test_000011",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "elderly",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:53:52.012190"
    },
    {
      "test_id": "test_000012",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_TP53",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.012225"
    },
    {
      "test_id": "test_000013",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.012253"
    },
    {
      "test_id": "test_000014",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.012277"
    },
    {
      "test_id": "test_000015",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML, NOS, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:53:52.012320"
    },
    {
      "test_id": "test_000016",
      "input_data": {
        "test_name": "blast_19_npm1_with_dysplasia",
        "description": "19% blasts with NPM1 mutation but significant dysplasia",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true,
          "TET2": true
        },
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:53:52.012360"
    },
    {
      "test_id": "test_000017",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.012382"
    },
    {
      "test_id": "test_000018",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "young_adult",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)",
      "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:53:52.012432"
    },
    {
      "test_id": "test_000019",
      "input_data": {
        "test_name": "who_mds_icc_aml_blast_15_cebpa",
        "description": "15% blasts with CEBPA bZIP - ICC may call AML, WHO may call MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA_bZIP",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA_bZIP",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:53:52.012468"
    },
    {
      "test_id": "test_000020",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.012490"
    },
    {
      "test_id": "test_000021",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.012525"
    },
    {
      "test_id": "test_000022",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.012557"
    },
    {
      "test_id": "test_000023",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.012582"
    },
    {
      "test_id": "test_000024",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.012606"
    },
    {
      "test_id": "test_000025",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "middle_aged",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:53:52.012649"
    },
    {
      "test_id": "test_000026",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, associated with germline DDX41 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, in the setting of germline DDX41 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => AML with NPM1 mutation, associated with germline DDX41 mutation",
        "Final classification => AML with NPM1 mutation, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => AML with mutated NPM1, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with germline DDX41 mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of germline DDX41 mutation",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T19:53:52.012687"
    },
    {
      "test_id": "test_000027",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:53:52.012710"
    },
    {
      "test_id": "test_000028",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS, hypoplastic (WHO 2022)",
      "icc_classification": "MDS, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "Hypoplasia detected => MDS, hypoplastic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, hypoplastic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, hypoplastic",
        "icc_classification": "MDS, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.012733"
    },
    {
      "test_id": "test_000029",
      "input_data": {
        "blasts_percentage": 8,
        "MDS_related_cytogenetics": {
          "del_7q": true
        },
        "MDS_related_mutation": {
          "RUNX1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "del7q_mds",
        "scenario_description": "del(7q) in MDS"
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:53:52.012756"
    },
    {
      "test_id": "test_000030",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.012788"
    },
    {
      "test_id": "test_000031",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "middle_aged",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:53:52.012807"
    },
    {
      "test_id": "test_000032",
      "input_data": {
        "test_name": "erythroid_blast_25_with_sf3b1",
        "description": "25% blasts with erythroid features and SF3B1 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 25,
        "AML_differentiation": "M6",
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
        "AML_differentiation: M6",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:53:52.012832"
    },
    {
      "test_id": "test_000033",
      "input_data": {
        "test_name": "blast_21_with_tet2_dnmt3a",
        "description": "21% blasts with TET2 and DNMT3A mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 21,
        "MDS_related_mutation": {
          "TET2": true,
          "DNMT3A": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): TET2, DNMT3A => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:53:52.012854"
    },
    {
      "test_id": "test_000034",
      "input_data": {
        "blasts_percentage": 28,
        "MDS_related_cytogenetics": {},
        "MDS_related_mutation": {
          "DNMT3A": true,
          "TET2": true,
          "ASXL1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "normal_karyotype_multiple_mutations",
        "scenario_description": "Normal karyotype with multiple mutations"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 28",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): DNMT3A, TET2, ASXL1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 28",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:53:52.012876"
    },
    {
      "test_id": "test_000035",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
        "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:53:52.012908"
    },
    {
      "test_id": "test_000036",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "pediatric",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)",
      "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:53:52.012952"
    },
    {
      "test_id": "test_000037",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.012987"
    },
    {
      "test_id": "test_000038",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.013025"
    },
    {
      "test_id": "test_000039",
      "input_data": {
        "blasts_percentage": 45,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "post_chemo_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 after chemotherapy"
      },
      "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy",
        "Final classification => AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:53:52.013071"
    },
    {
      "test_id": "test_000040",
      "input_data": {
        "test_name": "tr_blast_15_immune_intervention",
        "description": "15% blasts after immune intervention therapy",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "therapy_qualifier": "Immune interventions (ICC)",
        "MDS_related_mutation": {
          "TP53": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T19:53:52.013109"
    },
    {
      "test_id": "test_000041",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Diamond-Blackfan anemia"
        },
        "blasts_percentage": 20
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53, in the setting of Diamond-Blackfan anemia (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of Diamond-Blackfan anemia",
        "Qualifiers appended => AML with mutated TP53, in the setting of Diamond-Blackfan anemia (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53, in the setting of Diamond-Blackfan anemia",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T19:53:52.013154"
    },
    {
      "test_id": "test_000042",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.013177"
    },
    {
      "test_id": "test_000043",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.013211"
    },
    {
      "test_id": "test_000044",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.013243"
    },
    {
      "test_id": "test_000045",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.013264"
    },
    {
      "test_id": "test_000046",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.013298"
    },
    {
      "test_id": "test_000047",
      "input_data": {
        "blasts_percentage": 22,
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true,
          "del_17p": true
        },
        "MDS_related_mutation": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "complex_karyotype_tp53",
        "scenario_description": "Complex karyotype with TP53 mutation"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype, del_17p => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:53:52.013333"
    },
    {
      "test_id": "test_000048",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with low blasts and SF3B1 (WHO 2022)",
      "icc_classification": "MDS with mutated SF3B1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "SF3B1 mutation detected => MDS with low blasts and SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "SF3B1 mutation detected => MDS with mutated SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with mutated SF3B1 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_category": "MDS_SF3B1",
        "icc_category": "MDS_SF3B1",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.013356"
    },
    {
      "test_id": "test_000049",
      "input_data": {
        "test_name": "blast_18_with_runx1_runx1t1",
        "description": "18% blasts with RUNX1-RUNX1T1 fusion",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1_RUNX1T1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1_RUNX1T1",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1_RUNX1T1",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:53:52.013391"
    },
    {
      "test_id": "test_000050",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.013422"
    },
    {
      "test_id": "test_000051",
      "input_data": {
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "asxl1_runx1_poor_risk",
        "pattern_description": "ASXL1 + RUNX1 mutations - poor risk combination"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 16, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T19:53:52.013463"
    },
    {
      "test_id": "test_000052",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.013496"
    },
    {
      "test_id": "test_000053",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true,
          "1_x_TP53_mutation_del_17p": true,
          "1_x_TP53_mutation_LOH": true,
          "1_x_TP53_mutation_50_percent_vaf": true,
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "qualifiers": {},
        "blasts_percentage": 15
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True, '1_x_TP53_mutation_del_17p': True, '1_x_TP53_mutation_LOH': True, '1_x_TP53_mutation_50_percent_vaf': True, '1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: True, with del17p: True, with LOH: True, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T19:53:52.013527"
    },
    {
      "test_id": "test_000054",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.013561"
    },
    {
      "test_id": "test_000055",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.013581"
    },
    {
      "test_id": "test_000056",
      "input_data": {
        "blasts_percentage": 15,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:53:52.013613"
    },
    {
      "test_id": "test_000057",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_myeloid_malignancy": "Previous MDS"
        },
        "scenario_name": "aml_with_antecedent_mds",
        "scenario_description": "AML evolving from prior MDS - therapy-related scenario",
        "blasts_percentage": 35
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1, RUNX1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:53:52.013637"
    },
    {
      "test_id": "test_000058",
      "input_data": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true,
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "scenario_name": "post_radiation_mds",
        "scenario_description": "Radiation-induced MDS with del(5q)"
      },
      "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
        "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers: MDS with increased blasts 2, previous cytotoxic therapy",
        "Final classification => MDS with increased blasts 2, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:53:52.013682"
    },
    {
      "test_id": "test_000059",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:53:52.013720"
    },
    {
      "test_id": "test_000060",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.013756"
    },
    {
      "test_id": "test_000061",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with mutated NPM1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
        "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:53:52.013788"
    },
    {
      "test_id": "test_000062",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with BCR::ABL1 fusion (WHO 2022)",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 with blasts >=20 => AML with BCR::ABL1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with BCR::ABL1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with BCR::ABL1 fusion",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.013810"
    },
    {
      "test_id": "test_000063",
      "input_data": {
        "blasts_percentage": 25,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:53:52.013840"
    },
    {
      "test_id": "test_000064",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "blasts_percentage": 12
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with mutated TP53, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53, therapy related",
        "who_category": "MDS_TP53",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T19:53:52.013877"
    },
    {
      "test_id": "test_000065",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "young_adult",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "AML with CEBPA mutation (WHO 2022)",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:53:52.013899"
    },
    {
      "test_id": "test_000066",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.013923"
    },
    {
      "test_id": "test_000067",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_TP53",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.013957"
    },
    {
      "test_id": "test_000068",
      "input_data": {
        "blasts_percentage": 30,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T19:53:52.013986"
    },
    {
      "test_id": "test_000069",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014022"
    },
    {
      "test_id": "test_000070",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.014041"
    },
    {
      "test_id": "test_000071",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "AML with mutated NPM1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.014058"
    },
    {
      "test_id": "test_000072",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.014092"
    },
    {
      "test_id": "test_000073",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 25,
        "AML_differentiation": "M6a"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): ASXL1, SF3B1 => AML, myelodysplasia related",
        "AML_differentiation: M6a",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T19:53:52.014115"
    },
    {
      "test_id": "test_000074",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014147"
    },
    {
      "test_id": "test_000075",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.014180"
    },
    {
      "test_id": "test_000076",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014211"
    },
    {
      "test_id": "test_000077",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:53:52.014244"
    },
    {
      "test_id": "test_000078",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "young_adult",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)",
      "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T19:53:52.014288"
    },
    {
      "test_id": "test_000079",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "NRAS": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Previous MDS"
        },
        "scenario_name": "mds_to_aml_progression",
        "scenario_description": "MDS progression to AML with acquired mutations"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1, NRAS => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:53:52.014312"
    },
    {
      "test_id": "test_000080",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.014345"
    },
    {
      "test_id": "test_000081",
      "input_data": {
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "scenario_name": "immune_therapy_related",
        "scenario_description": "Post-immunotherapy myeloid neoplasm"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T19:53:52.014386"
    },
    {
      "test_id": "test_000082",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014417"
    },
    {
      "test_id": "test_000083",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation (WHO 2022)",
      "icc_classification": "MDS/AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.014453"
    },
    {
      "test_id": "test_000084",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "therapy_related_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 mutation - poor prognosis",
        "blasts_percentage": 65
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML with mutated TP53, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 65",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 65",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated TP53, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated TP53, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:53:52.014492"
    },
    {
      "test_id": "test_000085",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 1 (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP but blasts <10 => cannot label AML here",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.014519"
    },
    {
      "test_id": "test_000086",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "diagnostic_uncertainty",
        "significance": "high"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014550"
    },
    {
      "test_id": "test_000087",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.014570"
    },
    {
      "test_id": "test_000088",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.014604"
    },
    {
      "test_id": "test_000089",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, unclassifiable (WHO 2022)",
      "icc_classification": "MDS, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: True",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014627"
    },
    {
      "test_id": "test_000090",
      "input_data": {
        "blasts_percentage": 45,
        "MDS_related_cytogenetics": {
          "inv3_t33": true
        },
        "MDS_related_mutation": {
          "EVI1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "inv3_evi1_aml",
        "scenario_description": "inv(3) with EVI1 rearrangement"
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): EVI1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T19:53:52.014650"
    },
    {
      "test_id": "test_000091",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS, unclassifiable (WHO 2022)",
      "icc_classification": "MDS, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014677"
    },
    {
      "test_id": "test_000092",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation (WHO 2022)",
      "icc_classification": "MDS with excess blasts (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 but blasts <10 => cannot label AML here",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "MDS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "MDS with excess blasts",
        "who_category": "AML_GENETIC",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_category_difference",
        "significance": "high"
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T19:53:52.014708"
    },
    {
      "test_id": "test_000093",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "core_binding_factor_aml",
        "scenario_description": "Core-binding factor AML with good prognosis",
        "blasts_percentage": 45
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion (WHO 2022)",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T19:53:52.014729"
    },
    {
      "test_id": "test_000094",
      "input_data": {
        "test_name": "previous_mds_blast_18",
        "description": "18% blasts in patient with previous MDS diagnosis",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "previous_mds_mpn": "Previous MDS",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "category_difference",
        "significance": "medium"
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T19:53:52.014765"
    },
    {
      "test_id": "test_000095",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)",
      "icc_classification": "AML, NOS, therapy related (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T19:53:52.014804"
    },
    {
      "test_id": "test_000096",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation (WHO 2022)",
      "icc_classification": "AML with mutated TP53 (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T19:53:52.014836"
    },
    {
      "test_id": "test_000097",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014873"
    },
    {
      "test_id": "test_000098",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 2 (WHO 2022)",
      "icc_classification": "MDS/AML, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "AML",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "mds_aml_hybrid_difference",
        "significance": "medium"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014906"
    },
    {
      "test_id": "test_000099",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 0
      },
      "who_classification": "MDS, unclassifiable (WHO 2022)",
      "icc_classification": "MDS, NOS (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 0, fibrotic: False",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 0",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS",
      "icc_disease_type": "MDS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T19:53:52.014928"
    },
    {
      "test_id": "test_000100",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related (WHO 2022)",
      "icc_classification": "AML with myelodysplasia related cytogenetic abnormality (ICC 2022)",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "AML",
      "icc_disease_type": "AML",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": null,
        "significance": "low"
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T19:53:52.014953"
    }
  ],
  "timestamp": "2025-06-06T19:53:52.019352",
  "total_tests": 100
}